About this trial
Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.
Eligibility criteria
Qualifiers
Open fontanelle
Healthy preterm or term born neonates
Neonates with a medical condition of interest according to the different cohort studies: patent ductus arteriosus, perinatal asphyxia, stroke, pulmonary hypertension, congenital heart condition or infection/sepsis/meningitis
Neonates in need of procedures
Disqualifiers
Caregivers not understanding/speaking Norwegian or English
Caregivers not giving their consent
Trial design
Treatments tested in this trial
- NeoDoppler - CE certified
Treatment groups
Sponsors and collaborators
St. Olavs Hospital
Lead sponsor
Norwegian University of Science and Technology
Collaborator